Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Summary not available.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) has successfully closed its initial public offering, raising $11.0 million by issuing 1,226,668 units. Each unit comprises one share of common stock, and one Series A and Series B warrant. The Series A warrants are priced at $9.00 and will expire in five years, while Series B warrants have an exchange feature based on trading volume. The common stock began trading on June 30, 2020, on Nasdaq. The offering was managed by Dawson James Securities, with an option for underwriters to purchase up to an additional 184,000 shares.
Aditx Therapeutics has priced its initial public offering at $9.00 per unit, consisting of 1,226,668 units. Each unit includes one share of common stock, a Series A warrant, and a Series B warrant. The Series A warrants allow for purchase at $9.00, while the Series B warrants can be exercised at $11.25. The company has granted underwriters a 45-day option to purchase 184,000 additional units.
The shares will trade on Nasdaq under the ticker ADTX, beginning June 30, 2020. The company is focused on immune system technologies currently in the pre-clinical stage.